Suitable As Initial Therapy For Inflammatory And Degenerative
DICLOFENAC HAS POTENT ANTI-INFLAMMATORY, ANALGESIC AND ANTIPYRETIC ACTIONS. IT INHIBITS THE ENZYME, CYCLOOXYGENASE, THUS RESULTING IN REDUCED SYNTHESIS OF PROSTAGLANDIN PRECURSORS. ABSORPTION: RAPIDLY ABSORBED (ORAL SOLUTION, RECTAL SUPPOSITORY, IM); MORE SLOWLY (ENTERIC-COATED TAB). DISTRIBUTION: PENETRATES SYNOVIAL FLUID; ENTERS BREAST MILK (SMALL AMOUNTS). PROTEIN-BINDING: >99%. METABOLISM: EXTENSIVELY HEPATIC; CONVERTED TO METABOLITES. EXCRETION: ABOUT 60% EXCRETED IN URINE AS GLUCURONIDE AND SULFATE CONJUGATES; 35% IN BILE; 1-2 HR (ELIMINATION HALF-LIFE).
HISTORY OF GI ULCERATION; IMPAIRED CARDIAC, RENAL OR HEPATIC FUNCTION; HYPERTENSION; LACTATION. IV ADMIN IN PATIENTS WITH MODERATE OR SEVERE RENAL IMPAIRMENT; HYPOVOLAEMIA OR DEHYDRATION; ASTHMA, PORPHYRIA. MONITOR LFTS IN PATIENTS ON PROLONGED THERAPY. MAY PROLONG BLEEDING TIME; CAUTION WHEN USED IN PATIENTS WITH COAGULATION DISORDERS OR ON ANTICOAGULANTS. PROLONGED THERAPY MAY INCREASE RISK OF ANAEMIA. 1ST AND 2ND TRIMESTER OF PREGNANCY. ELDERLY, DEBILITATED PATIENTS.
PACKAGING:
1 ML AQ INJECTION (PAINLESS FORMULA) BLISTER PACK BOX WITH 10*5 INJECTION.